Navigation Links
AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedy's Disease)
Date:1/25/2011

SAN DIEGO, Jan. 25, 2011 /PRNewswire/ -- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).  Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy's Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients.  Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene.  ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).

"Given encouraging pre-clinical results and the clear need for a new therapeutic option for SBMA patients, ASC is excited to continue advancing preclinical development of this promising novel drug candidate," said ASC President Charles Shih, Ph.D. "The funding provided by the NINDS/NIH will significantly propel our efforts in validating ARD enhancers as a disease-modifying therapeutic intervention against such a rare and devastating neurodegenerative illness."

This $3.8 Million cooperative translational research grant will leverage expertise from the NINDS and draw upon ASC's innovative approach to targeting the mutant androgen receptor (AR).  The goals of the grant will be to first validate an orally administered ARD enhancer drug is efficacious in the SBMA transgenic animal model, and further, to complete preclinical toxicology, safety pharmacology, and ADME studies necessary in supporting of an IND filing to commence human clinical
'/>"/>

SOURCE AndroScience Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AndroScience Corporation Forms Strategic Alliance With Taiwan Based Orient Europharma to Develop Novel Topical Acne Therapeutic
2. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
3. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
4. Celsion Corporation Announces Completion of $5.1 Million Registered Direct Offering
5. CVS Caremark Corporation to Hold Fourth Quarter 2010 Conference Call
6. Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare
7. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
8. Luminex Corporation Fourth Quarter and Full Year 2010 Earnings Release Scheduled for February 7, 2011
9. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
10. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
11. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014 /PRNewswire/ ... of U.S. patient-level claims data, anemic chronic kidney ... with their erythropoiesis-stimulating agent (ESA) medication. In addition, ... Janssen,s Procrit. Other key findings ... in Nephrology: An Analysis of Erythropoiesis Stimulating Agents ...
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
Breaking Medicine Technology:Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... 23 OrbusNeich today announced that six-month follow-up ... and efficacy of the company,s Genous Bio-engineered R ... the treatment of de novo coronary artery disease. ... University of Ulm, Germany, principal investigator of the ...
... DEERFIELD, Ill. and LONDON, Sept. 23 Following today’s ... and the European Medicines Agency (EMA) for rosiglitazone in ... and Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s ... medications, and to the millions of people living with ...
Cached Medicine Technology:OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 2OrbusNeich's Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4
(Date:9/30/2014)... Health Day Reporter TUESDAY, Sept. ... are overweight or obese when diagnosed appear to face ... cancer, new research suggests. , , The finding didn,t ... the potential for developing other cancers associated with obesity. ... reported being overweight or obese prior to diagnosis had ...
(Date:9/30/2014)... WASHINGTON Legislation passed in 2003 to slow the ... government to treat Medicare patients has had no meaningful ... of researchers in the Journal of Clinical Oncology ... of outpatient chemotherapy to treat colorectal and lung cancers, ... oncologists prescribe those drugs following the implementation of the ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... by certified nutrition specialist and best-selling author Mike Geary that ... and totally transform their body into a fat-burning machine in ... Michaels, prompting an investigative review. , “In our culture ... it can be hard to decipher what is really fact ...
(Date:9/30/2014)... NY (PRWEB) September 30, 2014 ... hosted its annual “In Celebration” gala, honoring three ... nonprofit’s mission of striving to provide extraordinary and ... families facing a serious or life-limiting illness. , ... Club in Rye, NY and recognized William (Bill) ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... levels influence heart disease risk , , SUNDAY, Jan. 13 ... influence the risk of heart disease, have been identified ... three countries. , "I would predict that some of ... said the study,s senior author, Goncalo Abecasis, an associate ...
... Driving Global Breast Cancer Leader,s Promise ... Cancer Forever, ATLANTA, Jan. 12 Hala Moddelmog, president ... leader in the fight to end breast,cancer forever, today was ... Awards event in Atlanta with a ,High Heels in High,Places, ...
... Mandate Weakens After SEIU Contributes $450K to Prop ... ... "mean" or people will not be compelled to buy health insurance under the,Massachusetts ... financial projections for a similar plan pending in,California., As reported in the ...
... Department of,Environmental Protection is helping with efforts to ... 42-inch pipe ruptured Thursday evening between the city,s ... Island wastewater treatment plant.,The estimated 10 million gallons ... the treatment plant are, temporarily, being discharged into ...
... and lifestyle are at root of reduced risk, , , FRIDAY, Jan. ... your blood may reduce your risk of stroke, new research suggests. ... in their blood had a 42 percent lower risk of stroke ... is in the January issue of The American ...
... With a continued focus on,quality and efficiency ... focus on opportunities for streamlining processes to,maximize ... for,manufacturing organizations, the majority of the benchmark ... could provide several,worthwhile benefits, as found in ...
Cached Medicine News:Health News:Seven New Cholesterol Genes Discovered 2Health News:Seven New Cholesterol Genes Discovered 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:MA Proponent of Health Insurance Mandate Says 'Mean' Penalties Needed to Force People to Buy Insurance 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
10 mm wide tip....
Large. Double-ended. 3 mm pointed end and 5 mm angled end....
9 mm wide tip. Designated most popular model or size....
Medicine Products: